# Ocular Therapeutix (stock symbol: OCUL) Logo in transparent PNG and SVG formats

## Ocular Therapeutix Logo large

### Ocular Therapeutix Logo large Download PNG (64.85 KB)

![Ocular Therapeutix Logo large Download PNG (64.85 KB)](/img/orig/OCUL_BIG-cbfa6e21.png)

### Ocular Therapeutix Logo large Download SVG (13.72 KB)

![Ocular Therapeutix Logo large Download SVG (13.72 KB)](/img/orig/OCUL_BIG-e40a02ac.svg)

## Ocular Therapeutix Logo icon format

### Ocular Therapeutix Logo icon format Download PNG (28.84 KB)

![Ocular Therapeutix Logo icon format Download PNG (28.84 KB)](/img/orig/OCUL-28cdd69b.png)

### Ocular Therapeutix Logo icon format Download SVG (2.89 KB)

![Ocular Therapeutix Logo icon format Download SVG (2.89 KB)](/img/orig/OCUL-f4b8b5c8.svg)

## Ocular Therapeutix Logo large for dark backgrounds

### Ocular Therapeutix Logo large for dark backgrounds Download PNG (40.05 KB)

![Ocular Therapeutix Logo large for dark backgrounds Download PNG (40.05 KB)](/img/orig/OCUL_BIG.D-881f7cfd.png)

### Ocular Therapeutix Logo large for dark backgrounds Download SVG (13.7 KB)

![Ocular Therapeutix Logo large for dark backgrounds Download SVG (13.7 KB)](/img/orig/OCUL_BIG.D-3be78976.svg)

## Ocular Therapeutix Logo icon format for dark backgrounds

### Ocular Therapeutix Logo icon format for dark backgrounds Download PNG (28.84 KB)

![Ocular Therapeutix Logo icon format for dark backgrounds Download PNG (28.84 KB)](/img/orig/OCUL.D-56ac77aa.png)

### Ocular Therapeutix Logo icon format for dark backgrounds Download SVG (2.89 KB)

![Ocular Therapeutix Logo icon format for dark backgrounds Download SVG (2.89 KB)](/img/orig/OCUL.D-4ab2ab82.svg)

## About Ocular Therapeutix

Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology. The company markets ReSure Sealant, an ophthalmic device to prevent wound leaks in corneal incisions following cataract surgery; and DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing OTX-TKI, an axitinib intravitreal implant that is in phase 1 clinical trials for the treatment of wet age-related macular degeneration and other retinal diseases; OTX-TIC, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the Company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC, as well as a discovery collaboration with Mosaic Biosciences to identify new targets and therapeutic agents for the treatment of dry age-related macular degeneration (dMAD). Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.

1. Website domain: ocutx.com
2. Employees: 228
3. Marketcap: $0.48 Billion USD


## Categories
- [x] ðŸ‡ºðŸ‡¸ United States
- [x] ðŸ’Š Pharmaceuticals
- [x] ðŸ§¬ Biotech
